HHS withdraws request for drug importation proposals

The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries where they are typically cheaper and companies could “reimport” insulin to sell at a lower price. The RFPs were issued by the Trump Administration last year as part of an executive order directed at lowering drug prices. HHS today said it is “not aware that any proposals were received” in response to the RFPs and that it “intends to consider alternatives to the RFPs.”
Related News Articles
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…
Headline
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are…
Headline
The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to…